LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

5.35 -2.73

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

5.27

Max

5.49

Galvenie mērījumi
By Trading Economics
Ienākumi	-14M -14M
Pārdošana	-13M 6M
P/E Sektora vidējais	18.6 108.767
Peļņas marža	-238.621
Darbinieki	119
EBITDA	-13M -14M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+73.36% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	297M 945M
Iepriekšējā atvēršanas cena	8.08
Iepriekšējā slēgšanas cena	5.35

Ziņu noskaņojums

By Acuity

57%

43%

278 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

0.7658 / N/A Atbalsts un pretestība

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. febr. 23:53 UTC

Karstas akcijas

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

2026. g. 27. febr. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

2026. g. 27. febr. 17:55 UTC

Karstas akcijas

Toronto Stocks Decline, But Remain On Track for Weekly Gains

2026. g. 27. febr. 23:46 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

2026. g. 27. febr. 23:33 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

2026. g. 27. febr. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 27. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 27. febr. 21:30 UTC

Peļņas

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

2026. g. 27. febr. 21:30 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

2026. g. 27. febr. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

2026. g. 27. febr. 21:17 UTC

Peļņas

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

2026. g. 27. febr. 21:10 UTC

Iegādes, apvienošanās, pārņemšana

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

2026. g. 27. febr. 21:09 UTC

Iegādes, apvienošanās, pārņemšana

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

2026. g. 27. febr. 21:00 UTC

Peļņas

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

2026. g. 27. febr. 20:31 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

2026. g. 27. febr. 20:24 UTC

Tirgus saruna

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

2026. g. 27. febr. 20:23 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

2026. g. 27. febr. 20:12 UTC

Tirgus saruna

Nike Seen With Further Challenges in China -- Market Talk

2026. g. 27. febr. 19:44 UTC

Tirgus saruna

Gold Caps Historic Month -- Market Talk

2026. g. 27. febr. 19:39 UTC

Peļņas

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

2026. g. 27. febr. 19:38 UTC

Peļņas

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

2026. g. 27. febr. 18:53 UTC

Iegādes, apvienošanās, pārņemšana

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

2026. g. 27. febr. 18:45 UTC

Peļņas

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

2026. g. 27. febr. 18:45 UTC

Tirgus saruna

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

2026. g. 27. febr. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 27. febr. 17:07 UTC

Peļņas

Pemex Cuts 4Q Loss As Operating Results Improve

2026. g. 27. febr. 17:00 UTC

Tirgus saruna

Corn Rides Oil Momentum Higher -- Market Talk

2026. g. 27. febr. 16:31 UTC

Tirgus saruna

Canadian Economy Shows Resilience -- Market Talk

2026. g. 27. febr. 16:17 UTC

Tirgus saruna

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

2026. g. 27. febr. 15:49 UTC

Peļņas

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

73.36% augšup

Prognoze 12 mēnešiem

Vidējais 9.5 USD 73.36%

Augstākais 10 USD

Zemākais 7 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

278 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.